Cochrane · systematic review · CD006897
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
Walters, JAE, Tan, DJ, White, CJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 12.5%Low 1 · 12.5%Moderate 6 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySCS treatment for 7 or fewer days compared with SCS treatment for longer than 7 days for acute exacerbations of COPD
Population: patients with acute exacerbations of COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure Need for additional treatment SCS treatment for 7 or fewer days vs SCS treatment | OR 0.72 [0.36, 1.46] | 4 studies · 457 participants | Moderate Downgraded: imprecision |
Relapse New acute exacerbation or COPD‐related admission SCS treatment for 7 or fewer days vs SCS treatment | OR 1.04 [0.7, 1.56] | 4 studies · 478 participants | Moderate Downgraded: imprecision |
Adverse drug effect—hyperglycaemia SCS treatment for 7 or fewer days vs SCS treatment | OR 0.99 [0.64, 1.53] | 2 studies · 345 participants | Moderate Downgraded: imprecision |
Adverse drug effects Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression SCS treatment for 7 or fewer days vs SCS treatment | OR 0.88 [0.46, 1.7] | 5 studies · 503 participants | Low Downgraded: risk of bias, imprecision |
Mortality SCS treatment for 7 or fewer days vs SCS treatment | OR 0.91 [0.4, 2.06] | 2 studies · 336 participants | Moderate Downgraded: imprecision |
Length of hospitalisation (days) SCS treatment for 7 or fewer days vs SCS treatment | no estimate extracted | 3 studies · 421 participants | Moderate Downgraded: imprecision |
Lung function (end of treatment) FEV1 (L) SCS treatment for 7 or fewer days vs SCS treatment | no estimate extracted | 4 studies · 187 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Health‐related quality of life (QOL) Overall score (includes activity limitations, symptoms, fatigue, emotional functioning); scale 0 best to 6 worst; minimum important difference 0.5 SCS treatment for 7 or fewer days vs SCS treatment | no estimate extracted | 1 study · 271 participants | Moderate Downgraded: imprecision |
SCS treatment for 7 or fewer days compared with SCS treatment for longer than 7 days for acute exacerbations of COPD
Population: patients with acute exacerbations of COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure Need for additional treatment SCS treatment for 7 or fewer days vs SCS treatment | OR 0.72 [0.36, 1.46] | 4 studies · 457 participants | Moderate Downgraded: imprecision |
Relapse New acute exacerbation or COPD‐related admission SCS treatment for 7 or fewer days vs SCS treatment | OR 1.04 [0.7, 1.56] | 4 studies · 478 participants | Moderate Downgraded: imprecision |
Adverse drug effect—hyperglycaemia SCS treatment for 7 or fewer days vs SCS treatment | OR 0.99 [0.64, 1.53] | 2 studies · 345 participants | Moderate Downgraded: imprecision |
Adverse drug effects Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression SCS treatment for 7 or fewer days vs SCS treatment | OR 0.88 [0.46, 1.7] | 5 studies · 503 participants | Low Downgraded: risk of bias, imprecision |
Mortality SCS treatment for 7 or fewer days vs SCS treatment | OR 0.91 [0.4, 2.06] | 2 studies · 336 participants | Moderate Downgraded: imprecision |
Length of hospitalisation (days) SCS treatment for 7 or fewer days vs SCS treatment | no estimate extracted | 3 studies · 421 participants | Moderate Downgraded: imprecision |
Lung function (end of treatment) FEV1 (L) SCS treatment for 7 or fewer days vs SCS treatment | no estimate extracted | 4 studies · 187 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Health‐related quality of life (QOL) Overall score (includes activity limitations, symptoms, fatigue, emotional functioning); scale 0 best to 6 worst; minimum important difference 0.5 SCS treatment for 7 or fewer days vs SCS treatment | no estimate extracted | 1 study · 271 participants | Moderate Downgraded: imprecision |